Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.54 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.44 |
| ▸ | EP300 | Q09472 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29921081 | 1.00 | BRD4 (0.54) | BRD4CREBBPEP300KDM4EALDH1A1 | |
| SCHEMBL29920887 | 0.91 | BRD4 (0.54) | BRD4CREBBPEP300LMNA | |
| SCHEMBL29920781 | 0.91 | BRD4 (0.53) | BRD4CREBBPKDM4EALDH1A1LMNA | |
| SCHEMBL17797974 | 0.91 | BRD4 (0.53) | BRD4CREBBPKDM4EALDH1A1LMNA | |
| SCHEMBL16347959 | 0.91 | BRD4 (0.54) | BRD4CREBBPEP300LMNA | |
| SCHEMBL24728185 | 0.90 | BRD4 (0.51) | BRD4CREBBPEP300KDM4EALDH1A1 | |
| SCHEMBL29920673 | 0.90 | BRD4 (0.53) | BRD4CREBBPEP300KDM4EALDH1A1 | |
| SCHEMBL17798008 | 0.90 | BRD4 (0.46) | BRD4CREBBPEP300LMNA | |
| SCHEMBL17798167 | 0.90 | BRD4 (0.53) | BRD4CREBBPEP300KDM4EALDH1A1 | |
| SCHEMBL29921120 | 0.88 | BRD4 (0.50) | BRD4CREBBPEP300KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3849550-B1 | COMBINATION THERAPY FOR THE TREATMENT OF ESTROGEN-RECEPTOR POSITIVE BREAST CANCER | ZENITH EPIGENETICS LTD (CA) | 2024-08-07 | — | — | EP | claimed |
| WO-2023049257-A1 | METHODS FOR TREATING TRIPLE-NEGATIVE BREAST CANCER IN PRE-SELECTED PATIENT POPULATIONS WITH A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A PARP INHIBITOR | ZENITH EPIGENETICS LTD. (CA) | 2023-03-30 | — | — | WO | claimed |
| US-11607405-B2 | Combination therapy for the treatment of triple-negative breast cancer | ZENITH EPIGENETICS LTD. (CA) | 2023-03-21 | — | — | US | claimed |
| US-20220117942-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PROSTATE CANCER | ZENITH EPIGENETICS LTD. (CA) | 2022-04-21 | — | — | US | claimed |
| US-20220062246-A1 | COMBINATION THERAPY FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER | ZENITH EPIGENETICS LTD. (CA) | 2022-03-03 | — | — | US | claimed |
| US-20220047563-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ESTROGEN-RECEPTOR POSITIVE BREAST CANCER | ZENITH EPIGENETICS LTD (CA) | 2022-02-17 | — | — | US | claimed |
| EP-3849550-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ESTROGEN-RECEPTOR POSITIVE BREAST CANCER | Zenith Epigenetics Ltd. (CA) | 2021-07-21 | — | — | EP | claimed |
| EP-3849544-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PROSTATE CANCER | Zenith Epigenetics Ltd. (CA) | 2021-07-21 | — | — | EP | claimed |
| EP-3849549-A1 | COMBINATION THERAPY FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER | Zenith Epigenetics Ltd. (CA) | 2021-07-21 | — | — | EP | claimed |
| CN-112912075-A | Combination therapy for the treatment of prostate cancer | 恒翼生物医药科技(上海)有限公司 | 2021-06-04 | — | — | CN | claimed |
| WO-2020056232-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PROSTATE CANCER | ATTWELL SARAH CHRISTINE (CA) | 2020-03-19 | — | — | WO | claimed |
| WO-2020053655-A1 | COMBINATION THERAPY FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER | ZENITH EPIGENETICS LTD. (CA) | 2020-03-19 | — | — | WO | claimed |
| WO-2020053664-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ESTROGEN-RECEPTOR POSITIVE BREAST CANCER | ZENITH EPIGENETICS LTD. (CA) | 2020-03-19 | — | — | WO | claimed |
| EP-3010503-B1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD (CA) | 2020-03-11 | — | — | EP | claimed |
| US-10363257-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-07-30 | — | — | US | claimed |
| US-10010556-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-07-03 | — | — | US | claimed |
| US-20180161337-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2018-06-14 | — | — | US | claimed |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-08-03 | — | — | US | claimed |
| US-9663520-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | claimed |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. | 2016-06-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10363257-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | BRD4 1/4885CREBBP 24/4885EP300 15/4885 |
| US-10010556-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | BRD4 1/4885CREBBP 24/4885EP300 15/4885 |
| US-20180161337-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | BRD4 1/4885CREBBP 23/4885EP300 11/4885 |
| US-20220062246-A1 | COMBINATION THERAPY FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER | BRD4, PARP1, BRD3 | BRD4 1/4885CREBBP 162/4885EP300 41/4885 |
| US-11607405-B2 | Combination therapy for the treatment of triple-negative breast cancer | BRD4, PARP1, BRD3 | BRD4 1/4885CREBBP 162/4885EP300 41/4885 |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | BRD4 1/4885CREBBP 23/4885EP300 11/4885 |
| US-20220117942-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PROSTATE CANCER | BRDT, BRD4, BRPF3 | BRD4 2/4885CREBBP 85/4885EP300 5/4885 |
| US-20220047563-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ESTROGEN-RECEPTOR POSITIVE BREAST CANCER | CDK4, CDK6, BRD4 | BRD4 3/4885CREBBP 527/4885EP300 169/4885 |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | BRD4 1/4885CREBBP 23/4885EP300 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.